Browsing Tag
KLN-1010
1 post
Why Lilly’s $3.25bn Kelonia acquisition signals a manufacturing shift across the entire CAR-T landscape
Eli Lilly agrees to acquire Kelonia Therapeutics for up to $7B. What the iGPS in vivo CAR-T platform means for oncology and LLY investors. Read the analysis.